DENTSPLY SIRONA Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XRAY research report →
Range $10 – $14
Price Chart
About the company
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.
- CEO
- Daniel T. Scavilla
- IPO
- 1987
- Employees
- 14,000
- HQ
- Charlotte, NC, US
Get TickerSpark's AI analysis on XRAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.65B
- P/E
- -13.97
- Fwd P/E
- 6.05
- PEG
- -0.09
- P/S
- 0.48
- P/B
- 1.25
- EV/EBITDA
- 11.12
- Div Yield
- 1.88%
- Gross Margin
- 50.52%
- Op Margin
- 11.66%
- Net Margin
- -3.38%
- ROE
- -9.02%
- ROIC
- 9.96%
Latest fiscal year · YoY change
- Revenue
- $3.68B-3.0%
- Gross Profit
- $1.84B-6.0%
- Op Income
- $252.00M
- Net Income
- $-598,000,000+34.3%
- EPS
- $-3.00+33.0%
- OCF Growth
- -49.0%
- FCF Growth
- -63.0%
- 52W High
- $14.76
- 52W Low
- $8.14
- 50D MA
- $9.25
- 200D MA
- $11.12
- Beta
- 0.86
- RSI (14)
- 35
- Avg Volume
- 4.78M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DENTSPLY SIRONA’s Q3 was still down year over year, but management said it is seeing early U.S. and Wellspect momentum while trimming full-year guidance on continued pressure and ongoing investment.· November 5, 2026
- Q3 revenue was $836 million, down 7.6% reported and 7% in constant currency; adjusted EPS was $0.29, down $0.13 year over year.
- Management cut full-year guidance to about $3.5 billion of net sales and $1.20-$1.30 of adjusted EPS, versus prior sales of $3.5 billion-$3.6 billion and EPS of $1.40-$1.50.
- Wellspect Healthcare was a standout, with revenue up 10% to $92 million and described as delivering record sales and double-digit growth.
- U.S. dental showed early improvement: MIS sales grew double digits, value implants grew more than 7%, and U.S. endo returned to growth.
- The quarter included a $39 million pre-tax accounting-estimate benefit tied to inventory transfer accounting, but management said it was not an operating-performance gain and does not expect a similar benefit again.
Third-quarter revenue was $836 million, down 7.6% as reported and 7% in constant currency. Excluding Byte, about $10 million of planned dealer inventory reductions, and other discrete one-time events, revenue declined 3.8% in constant currency. Adjusted gross margin improved 190 basis points year over year, while adjusted gross profit declined approximately $20 million; adjusted EBITDA margin declined 110 basis points. Adjusted EPS was $0.29, down $0.13 from the prior-year quarter. Operating cash flow was $32 million versus $79 million a year ago, cash and cash equivalents were $195 million, and net debt to EBITDA was 3.4. Full-year 2026 guidance was lowered to approximately $3.5 billion in net sales and $1.20-$1.30 in adjusted EPS, excluding the $0.17 one-time tariff-refund gain; management said the $39 million pre-tax accounting benefit is included in guidance.
Dan Scavilla framed the quarter as continued progress on the Return-to-Growth Action Plan, but stressed that results are still not where they need to be. His message centered on stronger execution, more commercial investment, clinical education, and innovation, with particular emphasis on U.S. “green shoots,” MIS implants, endo, and Wellspect. He sounded constructive but measured, repeatedly saying the company is moving from stabilization toward growth, while also acknowledging that some of the progress is early and not yet broad-based.
John Fortson focused on the mechanics of the quarter and the outlook. He said revenue fell because of pressure across dental, the absence of Byte revenue, and planned dealer inventory reductions, while adjusted gross margin improved 190 basis points and operating cash flow came in at $32 million due mainly to unfavorable working capital. He also highlighted the $39 million pre-tax accounting estimate benefit from more detailed inventory transfer data, reiterated that it will not repeat in future periods, and said the company returned $25 million to shareholders via share repurchases year to date while keeping debt reduction as a core capital allocation priority.
Analysts pressed on the DSO opportunity, the meaning of the U.S. “green shoots,” the timing of inventory destocking, and whether the company can get U.S. growth to turn positive in Q4. Management said it has been building a stronger DSO team and sees DSOs as a long-term growth avenue, while also saying Wellspect strength should continue into next year and U.S. MIS/value implant momentum is tied to sales-force expansion and clinical education. On the accounting benefit, John Fortson said it is included in guidance because it was booked in the quarter, and Dan Scavilla added that offsetting one-time items make the net operational impact negligible.
The company is seeing real momentum in a few areas that matter: Wellspect posted record sales, U.S. MIS and value implants grew strongly, and U.S. endo returned to growth. Management also described improved sales coverage, better recruiting and retention, more clinical education, and expanding DSO engagement as signs that the Return-to-Growth plan is starting to take hold.
The core business is still under pressure, with revenue down in the quarter and full-year guidance cut on EMEA weakness, Middle East conflict impacts, dealer inventory reductions, freight costs, and ongoing investment. Management also said customers remain cautious on capital spending and that the Q3 accounting benefit is not recurring, so near-term results still depend on execution and market conditions improving rather than on a broad demand recovery.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.6%
- Shares Outstanding
- 199.35M
- Float Shares
- 196.47M
of shares held by institutions
389 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for XRAY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Jan 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jan 7, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Nov 3, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 2, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Nov 3, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 23, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Apr 19, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Apr 19, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Apr 11, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 21, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 2, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 15, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 2, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 15, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 26.12M | ▼ 587.82K |
| Vanguard Group Inc | 21.86M | ▼ 145.80K |
| Aqr Capital Management LLC | 11.83M | ▲ 1.37M |
| Vanguard Portfolio Management LLC | 11.40M | ▼ 384.19K |
| Fuller & Thaler Asset Management, Inc. | 9.77M | ▼ 2.92M |
| State Street Corp | 9.24M | ▼ 49.72K |
| Vanguard Capital Management LLC | 9.05M | ▲ 1.55K |
| Ariel Investments, LLC | 8.69M | ▲ 665.19K |
| Lazard Asset Management LLC | 6.24M | ▼ 2.03M |
| Geode Capital Management, LLC | 5.41M | ▼ 238.09K |
| Cooke & Bieler LP | 5.09M | ▼ 1.84M |
| Allianz Asset Management Gmbh | 4.77M | ▲ 946.72K |
Held by 427 ETFs
Biggest fund positions in XRAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Czerney Kevin | other | 2,273 |
| Nov 11, 26 | Barton-Brobst Lindi Rene | other | 1,704 |
| Sep 30, 26 | MAZELSKY JONATHAN JAY | other | 3,323.433 |
| Aug 10, 26 | Fortson John C. | other | 104,200 |
| Aug 10, 26 | Fortson John C. | other | 24,014 |
| Aug 7, 26 | Frohning Andrea L. | other | 802 |
| Jul 20, 26 | Fortson John C. | other | 0 |
| Jun 30, 26 | MAZELSKY JONATHAN JAY | other | 2,841.83 |
| Jun 12, 26 | MAZELSKY JONATHAN JAY | buy | 10,000 |
| Jun 8, 26 | Barton-Brobst Lindi Rene | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our XRAY coverage
Recent articles, reports, and earnings notes.

SmileDirectClub, IPO: What to Know Before It Lists
SmileDirectClub, Inc. is expected to list on NASDAQ on 2026-11-18, but the price range has not been disclosed. The company is a direct-to-consumer oral care and medtech platform built around teledentistry and clear aligners. Watch for how investors weigh fast revenue growth against regulatory risk, litigation, and leverage.

Inside the vVARDIS Holding AG IPO: Growth, Risks, and Verdict
vVARDIS Holding AG Class A is expected to list on the NYSE on 2026-11-13 in a priced IPO at $21.00 to $24.00 per share. The Swiss oral-health company is coming public with rapid revenue growth, but it is still loss-making and heavily dependent on U.S. adoption of its core product.

What to Watch as vVARDIS Holding AG Prices Its NYSE IPO
vVARDIS Holding AG is expected to list on the NYSE on 2026-11-13 under the symbol VVVV, with shares priced at $21.00 to $24.00. The Swiss dental company is pitching a first-in-category treatment for early-stage cavities, but investors will be watching how much of the story is already priced in. The bull case is rapid revenue growth and a large untapped dental market; the bear case is regulatory, supply-chain, and founder-overhang risk.
Want a deeper read on XRAY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Brickwood Asset Management LLP Sells 145,071 Shares of DENTSPLY SIRONA Inc. $XRAY
defenseworld.net · Nov 18
Dentsply Sirona: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
New Strong Sell Stocks for November 13th
zacks.com · Nov 13
DENTSPLY SIRONA Inc. (XRAY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
DENTSPLY SIRONA Q3 Earnings Call Highlights
marketbeat.com · Nov 6
XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut
zacks.com · Nov 6
Dentsply (XRAY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com · Nov 5
Dentsply International (XRAY) Q3 Earnings and Revenues Miss Estimates
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.